Portfoliotracker

Organogenesis Holdings Inc.

ORGO · NASDAQCM · Healthcare Drug Manufacturers - Specialty & Generic 0/100 E

0,803 $
▼ −0,007 (−0,86 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 12:36
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score0 / 100 Market cap104 mil. $ P/E– Forward P/E-1,5 P/S0,3 P/B0,9 EV/EBITDA– Dividend yield– FCF yield-0,06 % EPS-1,20 $ Net margin-38,4 % Return on equity-41,7 % Beta1,48 Debt / equity0,25
52-week range 0,73 to 6,20
3-month average volume0,8 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.

Employees
854
Country
United States
Fiscal year end
31. 12.
Data since
5. 1. 2017

Explore further

Similar companies STROFULCPTGXSLDBQTRX

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account